Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

I-Mab Biopharma Co., Ltd

http://www.i-mabbiopharma.com/en/

Latest From I-Mab Biopharma Co., Ltd

As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal

The deal will help MorphoSys focus on lifting lackluster Monjuvi sales, and on bringing its promising myelofibrosis candidate pelabresib to market.

Companies Commercial

ASCO Preview: Three Chinese Biotechs To Watch

BeiGene, Ascentage Pharma and I-Mab will be among the first Chinese pharma firms to report clinical trial results for their innovative drug candidates at this year’s ASCO meeting.

China Clinical Trials

US Delisting Risk Hits I-Mab Hard, Bilateral Agreement Needed?

It started with the risk of delisting from US stock markets over auditing requirements, but there are other underlying risks for Chinese bioventures that ultimately only some form of bilateral governmental agreement may need to address, but this may be increasingly hard to reach.

Financing Compliance

Financial Decoupling: China Biotechs Brace For Potential US Delistings, Softening Economy

US-listed Chinese biotechs face a potential double-whammy from US rules requiring accounting transparency at the risk of delisting, while other challenges loom from a general regulatory crackdown and economic softening in China, along with rising COVID-19 cases.

Policy Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Tasgen Biotech
    • Third Venture Biopharma
UsernamePublicRestriction

Register